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Abstract
Background: Tuberculosis (TB) is the largest cause of death in human immunodeficiency virus type 1 (HIV-1) infection,
having claimed an estimated one third to one half of the 30 million AIDS deaths that have occurred worldwide. Different
strains of Mycobacterium tuberculosis (MTb), the causative agent of TB, are known to modify the host immune response in a
strain-specific manner. However, a MTb strain-specific impact upon the regulation of HIV-1 replication has not previously
been established.
Methology/Principal Findings: We isolated normal human peripheral blood mononuclear cells (PBMC) and co-infected
them with HIV-1 and with either the well characterized CDC1551 or HN878 MTb clinical isolate. We show that HIV-1 co-
infection with the CDC1551 MTb strain results in higher levels of virus replication relative to co-infection with the HN878
MTb strain ex vivo. Furthermore, we show that the distinct pattern of CDC1551 or HN878 induced HIV-1 replication is
associated with significantly increased levels of TNF and IL-6, and of the transcription and nuclear translocation of the p65
subunit of the transcription factor NF-kB, by CDC1551 relative to HN878.
Conclusions/Significance: These results provide a precedent for TB strain-specific effects upon HIV-1 replication and thus
for TB strain-specific pathogenesis in the outcome of HIV-1/TB co-infection. MTb strain-specific factors and mechanisms
involved in the regulation of HIV-1 during co-infection will be of importance in understanding the basic pathogenesis of
HIV-1/TB co-infection.
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Introduction
Mycobacterium tuberculosis (MTb), the causative agent of tubercu-
losis (TB) disease, is the most frequent co-infection in human
immune deficiency virus type 1 (HIV-1) infected patients.
Furthermore, TB is thought to have caused a third to a half of
all acquired immune deficiency syndrome (AIDS) deaths that have
occurred to date [1,2], particularly in sub-Saharan Africa and
South East Asia [2,3], areas of world where HIV-1 infection is
expanding most rapidly.
TB in the setting of HIV-1 infection causes increased mortality
in part due to its activation of the innate and adaptive immune
system and subsequent production of specific cytokines and
intracellular signal transduction pathways resulting in the
induction of HIV-1 replication [4,5,6,7]. Increased HIV-1
replication in turn leads to higher viral loads, CD4+ T cell
destruction, and higher mortality in co-infected patients [7,8].
Moreover, the progressive immune compromise associated with
HIV-1 infection and AIDS results in reactivation of TB disease in
latently infected individuals, and an increase in primary TB and
secondary TB infection [8,9,10,11]. Notably, in severely immune
compromised AIDS patients, there is an extremely high mortality
within the first months after a diagnosis of TB [8,12,13],
particularly if the TB is drug resistant [14].
There is significant variation in MTb clinical isolates [15,16,17].
The clinical strains CDC1551 and HN878 provide two well-
characterized examples of clinical MTb isolates that have a
distinct impact upon the host immune response. CDC1551 was
originally characterized as hypervirulent due to its extensive
transmission from close and casual contacts [18]. However, when
compared to another clinical MTb isolate, HN878, in infected
mouse lung and in bone marrow derived macrophages (BMM),
the CDC1551 strain elicited a more vigorous pro-inflammatory
cytokine response [19,20]. The HN878 strain is significantly more
lethal than CDC1551 in murine TB models, and this lethality has
been attributed to a relative failure of HN878 to induce a prompt
and effective Th1-type immune response as compared to
CDC1551 [19,20,21]. The hypervirulent phenotype of HN878
has also been associated with specific differences in lipid
components of its cell wall (reviewed in: [22]), specifically to the
production and secretion of a highly active lipid-species-a
polyketide synthase (pks15/1)-derived phenolic glycolipid (PGL),
which dampened the host’s proinflammatory cytokine response
during TB infection in a mouse model [20].
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TB, does it also differentially regulate HIV-1 replication? Using
an ex vivo HIV-1/TB co-infection model, here we show that
infection of human peripheral blood mononuclear cells (PBMC)
with the CDC1551 MTb strain causes significantly higher viral
replication of clinical isolates representative of HIV-1 subtypes B,
C, and E, as compared to infection with HN878. Furthermore,
we show that deletion of PGL in the mutant HN878 strain
results in a minimal up-regulation of HIV-1 replication. Finally,
we demonstrate that the mechanism for this differential
regulation of HIV-1 involves differential production of TNF
and IL-6 and the transcription and nuclear localization of p65,
the activating subunit of the NF-kB complex. These results
provide evidence that HIV-1 regulation is influenced by TB
strain type in HIV-1/TB co-infection and may thus provide
insight into specific patterns of lethality in certain TB outbreaks
in patients with AIDS.
Results
CDC1551 infection results in higher HIV-1 replication as
compared to infection with HN878
We infected freshly isolated PBMC from eight normal PPD
positive donors with the MTb strains CDC1551 or HN878
overnight and infected the cultures with dual tropic (X4R5) viruses
that use both CXCR4 and CCR5 co- receptors for cellular entry,
from subtype B, C, and E HIV-1 (HIV-189.6, B subtype; HIV-
198IN17, C subtype; and HIV-193TH51, E subtype). Free virus levels
in the cellular supernatants were assessed at day 3, 7, and 10 post-
HIV-1-infection. In order to maximize the duration of cell survival
under co-infection conditions and thus observe maximal differ-
ences in viral replication, we infected the cultures with a low
concentration of HIV-1 (50 TCID50).
HIV-1 replication was higher in all cultures co-infected with
MTb (all three strains) compared to cultures infected with HIV-1
alone (Figure 1A). Strikingly, CDC1551 infection of PBMC
resulted in significantly higher levels of HIV-1 replication at day
10 post-HIV-1-infection of all three HIV-1 subtypes (p#0.05)
(Figure 1A). Thus, different MTb strains distinctly regulate the
dual tropic subtype B, C, and E HIV-1 isolates tested. We next
investigated whether a CXCR4 dependent T cell tropic HIV-1
isolate (HIV-1LAI) was also differentially regulated by co-infection
with CDC1551 and HN878. We found that, p24 levels were
significantly higher in CDC1551 infected cultures using HIV-
1LAI (Figure 1B) similar to our results using dual tropic X4R5
viruses.
Since previous studies showed that the PGL from HN878
inhibited inflammatory cytokine production in murine bone
marrow macrophages (BMM) [20], we next tested whether a
mutant strain of HN878 (HN878 pks1-15::hyg) containing a
deletion in the gene encoding this PGL differentially regulated
HIV-1 as compared to the parental HN878 strain. In cultures co-
infected with HN878 pks1-15::hyg, HIV-1 replication was non-
significantly higher than in the cells co-infected with wild type
HN878 (Figure 1B) suggesting that this distinct lipid in the HN878
cell wall is not a major determinant of differential HIV-1
replication in this system. We analyzed the formation of colony-
forming units (CFU) after infection by both bacterial strains and
found no significant difference in bacterial number at day 4 and 7
post infection of the PBMC cultures (data not shown). We note
that it has previously been shown that the in vitro growth rates of
CDC1551 and HN878 are very similar [23]. Taken together,
these results show that HIV-1 replication is differentially
influenced by different MTb isolates.
CDC1551 and HN878 differentially regulate the host
immune response in human PBMC
Previous studies using murine lung and BMM showed that
CDC1551 and HN878 differentially induced a number of host
factors involved in the innate immune response including TNF,
IL-10, IL-6, and IL-12 [19,20,21]. In human macrophages it was
also shown that TNF and IL-12 were differentially induced by
CDC1551 and HN878 [24]. Furthermore, in murine cells it was
shown that the HN878 PGL was critical in the regulation of TNF,
IL-6, and MCP-1 since deletion of the PGL in the HN878 mutant
(HN878 pks1-15::hyg) resulted in higher levels of these factors,
which was associated with enhanced survival of TB infected mice
[20].
We thus next examined the levels of TNF, IL-1b, IL-2, IL-6,
IL-10, and MCP-1 (also known as CCL2) in human PBMC
infected by CDC1551, HN878, and HN878 pks1-15::hyg 2 and 4
days post-MTb infection. As shown in Figure 2, a significantly
higher amount of TNF, IL-6, and MCP-1 was detected in
supernatants from PBMC infected with CDC1551 as compared
to cultures infected with HN878. Furthermore, infection with
HN878 pks1-15::hyg resulted in non-significant increase of these
cytokines as compared to wild type HN878 in each case
(Figure 2). By contrast, we did not detect significantly higher
levels of IL-1b, IL-2, and IL-10 in PBMC cultures infected with
CDC1551 as compared to those infected with HN878 (Figure 2).
To test whether co-infection with HIV-1 might influence
cytokine levels in this co-infection model, we also evaluated
cytokine levels in PBMC cultures co-infected with the three
isolates of HIV-1 representing B, C, and E subtypes and with
CDC1551 and HN878. We found no difference in the levels of
cytokines measured (data not shown). Thus, the infecting TB
strain is the determinant factor in the levels of TNF, IL-6 and
MCP-1. CDC1551 infection results in significantly higher levels
of these factors relative to HN878 infection. Similar to the lack
of a significant effect upon HIV-1 replication, the PGL deletion
in HN878 did not have a significant effect on the regulation of
TNF, IL-6 and MCP-1 levels by HN878.
Inhibition of CDC1551-induced TNF and IL-6 significantly
decreases HIV-1 replication in a dose-dependent manner
Since we observed differential induction of TNF, IL-6, and
MCP-1 in human PBMC, all factors that increase HIV-1
replication [25,26,27], we next investigated the effect of blocking
TNF, IL-6, or MCP-1 upon HIV-1 replication in CDC1551 co-
infected cultures. Using PBMC from six donors we blocked TNF,
IL-6, and MCP-1 function by increasing concentrations of
neutralizing monoclonal antibodies to these proteins and used a
mouse IgG1 isotype antibody as a control. The cells were then
infected with CDC1551 and 42 hours later co-infected with HIV-
1LAI. As shown in Figure 3, virus replication was significantly
inhibited in a concentration-dependent manner by antibodies to
TNF at 2 mg/ml (p,0.05) and IL-6 at 5 mg/ml (p,0.05)
comparison to the non-specific effects of an isotype control
antibody (Figure 3). Virus replication was further significantly
decreased when a mixture of blocking antibodies to TNF, IL-6,
and MCP-1 (at 2 ug/ml and 5 ug/ml of each antibody) was added
to the cell cultures co-infected with CDC1551 and HIV-1
(p,0.01) (Figure 3). Blocking of MCP-1 lowered p24 levels but
not significantly in comparison to the non-specific effects of an
isotype control antibody (Figure 3). Thus, we conclude that in
CDC1551-infected PBMC, the higher levels of TNF and IL-6
functionally contribute to the higher levels of p24 relative to
PBMC infected with HN878.
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regulate p65 transcription and nuclear translocation
One of the mechanisms by which MTb increases HIV-1
replication is by promoting the nuclear translocation of transcrip-
tion factors required for activation of HIV-1 transcription via its
long terminal repeat (LTR) [5,28,29]. Upon MTb ligation of Toll
like receptors (TLR), several signal transduction cascades are
stimulated, including the cascade leading to NF-kB translocation
to the nucleus [30]. Furthermore, TNF and MCP-1 both increase
nuclear NF2kB levels after engaging their own cognate receptors
[30,31,32]. Since NF-kB is recruited to the HIV-1 LTR of all
subtypes [5,25,33,34,35] and is a critical factor in HIV-1
replication, we thus next investigated the impact of MTb strain
variation upon the transcription and nuclear translocation of the
activating NF-kB subunit, p65.
We infected PBMC from six normal PPD-positive individuals
with CDC1551, HN878 or HN878 pks1-15::hyg for 3, 8 and
24 hours and then extracted whole cell RNA and measured p65
mRNA levels using real time PCR. As shown in Figure 4A, there
was not a significantly difference in p65 mRNA levels across the
cells infected with the three MTb strains and uninfected cells at 3
and 8 hours post infection. However, CDC1551 infection
significantly increased p65 mRNA levels compared to HN878
24 hours after infection (p,0.05). In addition, p65 mRNA levels
Figure 1. HIV-1 replication is differentially regulated by different strains of MTb. (A) HIV-1 p24 levels produced by co-infection of PBMC
with different TB strains and X4R5 viruses from subtype B (HIV-189.6), C (HIV-198IN17) and E (HIV-192TH51). PBMC from eight different donors were
infected in duplicate with the MTb strain CDC1551 or HN878 and then infected with HIV-189.6, HIV-198IN17, and HIV-192TH51, the next day. Virus
replication was significantly higher in the cultures co-infected with the MTb strain CDC1551 as compared to HN878 at day 10 post-infection with HIV-
189.6, HIV-198IN17 and HIV-192TH51 (*, p,0.05). Results are shown as mean6SEM. (B). HIV-1 p24 levels produced by co-infection of PBMC with different
TB strains and X4 HIV-1LAI (B subtype). PBMC from eight different donors were infected in duplicate with the MTb strain CDC1551, HN878, or HN878
pks1-15::hyg and then infected with HIV-1LAI. Virus replication was significantly higher in the cultures co-infected with the MTb strain CDC1551 as
compared to HN878 (*, p#0.05 at day 7 and 10 post-infection). In the cultures co-infected with HN878 pks1-15::hyg, virus replication was non-
significantly higher at day 7 (1.3 fold) and day 10 (1.4 fold) as compared to the cultures co-infected with wild type HN878. Results are shown as
mean6SEM.
doi:10.1371/journal.pone.0006116.g001
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15::hyg compared with cells infected with HN878 (Figure 4A).
We also investigated the nuclear translocation of p65 in PBMC
from six PPD-positive normal donors infected by the three MTb
strains for 24 hours. Using nuclear extracts prepared from
individual donor PBMC, we performed EMSAs with an
oligonucleotide matching the proximal NF-kB consensus motif
from the HIV-1LAI LTR. Figures 4B and 4C show a representative
experiment from a single individual from six individuals’ PBMC
that were evaluated in this manner. We detected an inducible
complex in cells infected with CDC1551 (Figure 4B, lane 2), which
was demonstrated to be the p65 subunit by its reactivity with an
antibody to p65 (Figure 4C, compare lanes 2 and 3). Furthermore,
we detected an increase of p65 binding after infection with
CDC1551 relative to HN878 (Figure 4B, compare lanes 2 and 3).
We note that after infection with the HN878 mutant (HN878 pks1-
15::hyg) there was increased levels of p65 compared to HN878,
(Figure 4B, compare lanes 3 and 4). To quantify the increased
binding in infected cells from the six individuals evaluated, we
performed densitometric analysis of the p65 band from the
autoradiographs of the EMSA experiments using the PBMC from
the six individual donors (Figure 4D). This demonstrated that
there were significantly higher p65 levels in CDC1551 infected
cells compared to HN878 infected cells, and that the deletion of
PGL from HN878 non-significantly increased p65 levels
(Figure 4D), consistent with the experiments presented in
Figures 4B and 4C.
Discussion
Although MTb clinical strains with distinct immune modulatory
characteristics have been identified, the effect of MTb phenotypic
Figure 3. Blocking TNF or IL-6 decreases HIV-1 replication
significantly in a dose dependent manner. Virus replication was
determined by measuring HIV-1 p24 levels in the culture supernatants
in PBMC from six individual donors at day 7 post-infection performed in
duplicate. Blocking TNF (at 2 ug/ml or 5 ug/ml) or IL-6 (5 ug/ml)
significantly decreased virus replication (*, p,0.05) as compared to the
same concentrations of an IgG1 control antibody. Blocking of MCP-1
alone on average minimally decreased HIV-1 replication, but this did
not reach statistical significance. Virus replication was further signifi-
cantly inhibited in cultures containing a mixture of blocking antibodies
to TNF, IL-6, and MCP-1 at a concentration of 2 mg/ml and 5 mg/ml (**,
p,0.01). Results are shown as mean6SEM.
doi:10.1371/journal.pone.0006116.g003
Figure 2. CDC1551 and HN878 infection differentially regulate
TNF, IL-6 and MCP-1 in human PBMC. PBMC from eight different
donors were infected in duplicate with the MTb strain CDC1551, HN878,
or HN878 pks1-15::hyg for 2 or 4 days and levels of TNF, IL-6 and MCP-1
were assessed. Production of TNF, IL-6 and MCP-1 was significantly
higher in CDC1551 infected cells as compared to HN878 infected cells
(*p,0.05; **, p,0.01; ***, p,0.005). Infection of PBMC with HN878
pks1-15::hyg non-significantly increased the production of these cellular
factors as compared to infection with HN878. Expression of IL-1b, IL-2
and IL-10 were also on average minimally higher in CDC1551 versus
HN878 infected cells, but not significantly.
doi:10.1371/journal.pone.0006116.g002
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infection is unknown. In this study we have shown for the first time
that distinct activation of the host immune response by
phenotypically distinct MTb clinical strains directly regulates
HIV-1 replication in an ex vivo co-infection model.
Recognition of MTb by phagocytic cells leads to immune
activation and induction of a complex series of interactions
between various cell populations [36,37,38], which results in the
production of a large number of cytokines and chemokines that
are involved in TB and AIDS disease outcome in co-infected
patients [4,5,39,40,41,42]. Specifically, the induction of inflam-
matory molecules such as TNF, IL-6, and MCP-1 by active MTb
infection is important for inhibition of TB disease progression
[5,43,44], while at the same time these same molecules enhance
HIV-1 replication [25,26,27,34,45,46,47] (Figure 3).
The binding of TNF as well as MCP-1 to their cognate
receptors induces the activation of the IkB kinase complex and
the nuclear translocation of active NF-kB [30,31,32,48]. In
addition, IL-6, TNF, and MCP-1 signaling triggers a cascade of
events in the cell that results in the activation of the AP-1
transcription factor complex ([49,50,51]. In the nucleus, NF-kB
and AP-1 bind to their cognate sites on the HIV-1 LTR and
thereby enhance virus transcription [25,33,50,51,52,53]. Further-
more, NF-kB and AP-1 serve as critical regulators of the
inducible expression of many host factors that are important for
upregulation of HIV-1 replication ([32,49,54,55], and reviewed
in [56]). Here, we have demonstrated that levels of TNF and IL-
6 and the transcription and DNA binding of NF-kBi s
significantly and differentially regulated by infection by two
distinct MTb strains, HN878 or CDC1551. These results
demonstrate a correlation between infection by two distinct
MTb strains and their differential effect upon the innate and
adaptive immune system, which is consistent with their
differential impact upon HIV-1 replication.
Transcription mediated by the HIV LTR depends on
cooperative interactions among transcription factors and other
cofactors, such as P-TEFb and Tat. Although the differential effect
of CDC1551 and HN878 on virus replication is clearly
multifactorial, given the importance of NF-kB in HIV-1 gene
transcription, even a small effect upon its concentration and
binding to the LTR could have a large functional impact [57,58].
Figure 4. CDC1551 and HN878 differentially induce transcrip-
tion and nuclear localization of the p65 subunit of NF-kB. (A)
p65 mRNA levels in PBMC from six individual donors infected with
CDC1551, HN878, or HN878 pks1-15::hyg for 3, 8 and 24 hours. There
was no significant difference in p65 mRNA levels across uninfected cells
and the cells infected with CDC1551, HN878, or HN878 pks1-15::hyg
after 3 and 8 hours infection. A significant difference in p65 mRNA
levels was observed 24 hours after infection in CDC1551 infected cells
as compared to HN878 infected cells (*, p,0.05). (B) A representative
EMSA analysis using nuclear extracts from PBMC infected with
CDC1551, HN878, and HN878 pks1-15::hyg for 24 hours. DNA binding
activity of NF-kB was higher in nuclear extracts prepared from cells
infected with CDC1551 as compared to HN878 (lanes 2 and 3). Infection
with HN878 pks1-15::hyg increased NF-kB DNA binding activity as
compared to HN878. (lanes 2, 3 and 4). The gel shown is representative
of EMSAs performed using nuclear extracts prepared from PBMC from
six individual donors. (C) The induced complex seen on EMSA contains
the activating p65 subunit of NF-kB. An antibody to p65 specifically
reacted with the complex that is differentially increased by CDC1551
and HN878, specifically inhibiting the formation of the p65 complex in
lane 3 relative to the complex in lane 2. When quantified by
densitometric analysis the inhibition of the complex after antibody
reaction was 57%. (D) Increased nuclear translocation of the p65 NF-kB
subunit after infection with CDC1551 as compared to HN878. The
histogram shows an average of the densitometric analyses of the p65
band from autoradiographs of the EMSAs from nuclear extracts
prepared from the six donors whose PBMC were either uninfected or
infected with CDC1551, HN878, or HN878 pks1-15::hyg as indicated. The
results are shown as mean6SEM and demonstrate that there was
significantly higher p65 levels in CDC1551 than in HN878 infected cells.
(*, p,0.05).
doi:10.1371/journal.pone.0006116.g004
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between p65 mRNA and nuclear protein levels in CDC1551 and
HN878 infected cells demonstrates one specific mechanism that
might underlie differential activation of replication by the two TB
strains.
It is thus reasonable to surmise that infection with phenotyp-
ically distinct MTb strains can potentially result in different viral
loads in vivo, and to different patterns of disease progression in co-
infection. Notably, intrapatient HIV-1 heterogeneity and diversity
of virus quasispecies have previously been associated with TB/
HIV-1 co-infection [39,40]. An implication of the findings
presented here may thus be that certain MTb strains such as
CDC1551, which cause higher levels of HIV-1 replication relative
to other MTb strains like HN878, may differentially enhance the
emergence of relatively more virulent and drug-resistant HIV-1
isolates.
One of the main factors that determine the unique phenotypic
characteristics of HN878 and CDC1551 strains is their distinct
cell wall composition [20]. In animal models it has been shown
that PGL, which is present in HN878 and not in CDC1551,
plays an important role in hypoimmunogenicity and thus the
hyperlethality associated with HN878 infection [20]. Here, we
have shown that PGL is not a significant factor in virus
replication elicited by HN878, although co-infection with HN878
pks1-15::hyg (lacking PGL production) was higher than that
observed for HN878 and resulted in higher levels of p65 mRNA
and nuclear localization of the factor itself. Thus, although it
may play a role, our observations are consistent with the
conclusion that the lower level of HIV-1 replication and cytokine
and chemokine production elicited by HN878 as compared to
CDC1551 is multifactorial and involves the differential expres-
sion of other MTb genes.
CDC1551 is a member of the Latino-American and
Mediterranean (LAM) mycobacterial family and is a member
of principal genetic group 2 (PGG 2) [59,60]. By contrast,
HN878 is a member of W-Beijing family of isolates [61,62] and
belongs to PGG 1 [63]. In 2006 a study from KwaZulu Natal
(KZN), South Africa described an outbreak of extensively drug
resistant (XDR)-TB in the context of advanced AIDS infection
where 52 of 53 patients died very rapidly within a median time
of 16 days post-TB diagnosis [14]. Subsequent genetic analysis of
the bacterial strains causing this outbreak revealed that it was
caused by another LAM family member the F15/LAM4/KZN
strain [64], which also belongs to the principal genetic group 2
(PGG 2) [63]. Thus, it is intriguing to speculate that there are
pathogenesis factors that are separate from drug resistance
profiles that contribute to the high mortality in certain HIV-1/
TB co-infected patients. Thus, we expect that future studies may
identify additional mechanisms of direct interaction of HIV-1
with specific MTb clinical strains that will lead to understanding
distinct patterns of pathogenesis in HIV-1/TB co-infected
patients.
In summary, we have shown for the first time that infection by
different MTb strains results in distinct levels of HIV-1 replication.
We have linked this observation to the distinct regulation of
cytokine expression, and to the activation of NF-kB. Thus, HIV-1
replication and progression to AIDS as well as TB disease outcome
in HIV-1/TB co-infection is likely to reflect not only variable host
factors, but also the variation of the MTb strains and expression of
bacterial factors that interact with the host. Further investigation
to determine MTb strain-specific factors and mechanisms
responsible for the increase in AIDS and TB disease progression




MTb clinical strains CDC1551, HN878, and HN878 pks1-
15::hyg were prepared by adding 50 ml of frozen bacteria stock into
10 ml of Middlebrook 7H9 medium (Difco BD, Franklin Lakes,
NJ) supplemented with albumin dextrose complex (ADC) and
0.05% Tween 80 (Sigma-Aldrich, Saint Louis, MO). The growth
rates of these MTb strains in in vitro culture is very similar, with
HN878 showing a doubling time of 16.7 h and CDC1551 a
doubling time of 17.1 h. [23]. Each strain was grown to an OD650
of 0.4 at 37uC, which assured that they were in the logarithmic
growth phase. Cells were then pelleted and washed with PBS and
re-suspended in RPMI 1640 and passed through a 5 mm filter to
ensure that the bacteria were in a single cell suspension. Bacterial
cell numbers were determined by measurement of OD650 before





HIV-1LAI was obtained from The Centralized Facility for AIDS
Reagents, National Institute for Biological Standard and Control
(NIBSC), United Kingdom. HIV-189.6, HIV-198IN17, and HIV-
193TH51 were obtained from the NIH AIDS Research and
Reference Reagent Program, USA. High titers of viral stocks
were prepared by infection of a pool of normal human donor
PBMCs stimulated with phytohemoglutinin (PHA) (Sigma-Al-
drich) and IL-2 (AIDS Research and Reference Reagent
Program). Supernatants containing high titers of viable virus were
aliquoted and stored at 270uC.
MTb and HIV-1 infection of cultured PBMC
PBMC were isolated from eight normal PPD positive donors
and cultured in 24-well plates at 1.5610
6 in 1.5 ml RPMI 1640
medium (BioWhittaker, Inc., Walkersville, MD) supplemented
with 10% heat-inactivated fetal calf serum (FCS) (Gemini Bio-
Products, Woodland, CA) and 2 mM L-glutamine. Cells were
immediately infected with 1.5610
5 MTb at a 1:10 ratio of bacteria
to cells and incubated at 37uC and 5% CO2 for approximately
10 hours. We stained the cells with CD14-FITC and performed
flow cytometry analysis and found an average of 10% monocytes
in samples from the donors used. The cultures were then mock
infected or infected with 50 TCID50 HIV-1. Uninfected cultures
and cultures infected with HIV-1 alone were also set up as
controls. At day 2, 4, 7, and 10 post-infection, culture supernatants
were collected and stored at 270uC until analysis.
ELISA
Cytokine (IL-1b, IL-2, IL-6, IL-10, TNF) or chemokine
(monocyte chemotactic protein-1 [MCP-1]) levels in cell culture
supernatants were measured using OptEIA ELISA kits (BD-
Pharmingen, Franklin Lakes, NJ). Cell-free virus levels were
determined by measuring HIV-1 p24 antigen levels in culture
supernatants using the HIV-1 p24 ELISA Kit (PerkinElmer,
Boston, MA).
Antibody neutralization assay
Increasing concentrations of neutralizing monoclonal antibodies
to TNF, IL-6 (R&D Systems, Minneapolis, MN), MCP-1
(eBioscience, San Diego, CA), or mouse IgG isotype control
(R&D Systems) were added to 1.5610
6 freshly isolated PBMC
from six PPD-positive donors in complete RPMI 1640 media
supplemented as above in 24-well plates just prior to infecting the
cells with the MTb strain CDC1551 as described above. Antibody
TB Regulation of HIV-1
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concentration that had no effect on cell viability and activation.
Cultures were incubated at 37uC for 42 hours and then infected
with HIV-1LAI and cell-free virus levels were measured at day 7
post-HIV-1 infection as described above.
Quantitative PCR
The mRNA expression level of the p65 subunit of NF-kB was
determined by real-time PCR using SYBR green (Applied
Biosystems, Foster City, CA). The reaction conditions were
95uC for 10 min followed by 40 cycles of 95uC for 20 sec and
60.5uC for 1 min. The results were normalized using b-actin
mRNA as an internal control and expressed as relative values.
Nuclear protein extract preparation and electrophoretic
mobility shift assay
PBMC from six normal donors were infected with CDC1551,
HN878, or H878 pks1-15::hyg, or mock infected as described above
(1610
7cells per infection condition). After 24 hours, the cells were
harvested, and nuclear extracts were prepared from infected and
uninfected cells and passed through 0.2 mm filters to remove
infectious MTb from the lysates. Electrophoretic mobility shift
assays (EMSAs) were then performed as previously described
[65,66] using synthetic oligonucleotides corresponding to one of
the NF-kB binding motifs in the HIV-1LAI LTR (59-
CGCTGGGGACTTTCCAGG-39). The anti-p65 antibody used
in the supershift assays was purchased from Santa Cruz
Biotechnology (SantaCruz, CA). Images of gels were captured
using a Molecular Dynamics phosphorimaging system. Densito-
metric analysis was performed on the p65 complex using
Quantity1 analysis (Biorad, CA) software. All values in each
experiment were normalized to the p65 band in experiments with
unstimulated cells. Results of the 6 individuals were averaged and
are displayed with SEM.
Statistical analysis
Where applicable, results are expressed as a mean6SEM.
Comparison between two groups was performed using the paired
Student t-Test with the aid of Microsoft Excel software. p#0.05
was considered significant.
Acknowledgments
We are grateful to Ricardo Rajsbaum for technical assistance in the
beginning stages of this study, and to James Falvo for comments on the
manuscript.
Author Contributions
Conceived and designed the experiments: SR HB AEG. Performed the
experiments: SR HB AM NAS. Analyzed the data: SR HB AM EJR AEG.
Wrote the paper: SR HB AEG.
References
1. UNAIDS (2006) Report on the global AIDS epidemic 2006. http://
wwwunaidsorg/en/HIV_data/2006GlobalReport/defaultasp.
2. UNAIDS (2007) TB-HIV: Networking for Policy Change. A Participant’s
Guide, http://wwwwhoint/tb/hiv/en/.
3. Organization WH (2007) Global Tuberculosis control: surveillance, planning,
financing. WHO report 2005. http://wwwwhoint/tb/publications/global_
report/2005/en.
4. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, et al. (1996)
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune
activation. J Immunol 157: 1271–1278.
5. Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, et al. (2002) Maximal
HIV-1 replication in alveolar macrophages during tuberculosis requires both
lymphocyte contact and cytokines. J Exp Med 195: 495–505.
6. Havlir DV, Torriani FJ, Schrier RD, Huang JY, Lederman MM, et al. (2001)
Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble
type II TNF receptor, and transforming growth factor beta levels in human
immunodeficiency virus type 1-infected individuals with Mycobacterium avium
complex disease. J Clin Microbiol 39: 298–303.
7. Toossi Z, Mayanja-Kizza H, Lawn SD, Hirsch CS, Lupo LD, et al. (2007)
Dynamic variation in the cellular origin of HIV type 1 during treatment of
tuberculosis in dually infected subjects. AIDS Res Hum Retroviruses 23:
93–100.
8. Goldfeld AE, Ranjbar s, Tsitsikov EN (2008) Tuberculosis/human immunode-
ficiency virus coinfection and the host immune response. In: Kaufmann SHE,
Britton WJ, eds (2008) Handbook of Tuberculosis: Immunology and Cell
Biology. Weinheim: WILEY-VCH Verlag GmbH & KGaA.
9. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, et al. (1992)
An outbreak of tuberculosis with accelerated progression among persons infected
with the human immunodeficiency virus. An analysis using restriction-fragment-
length polymorphisms. N Engl J Med 326: 231–235.
10. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, et al. (1999)
Exogenous reinfection as a cause of recurrent tuberculosis after curative
treatment. N Engl J Med 341: 1174–1179.
11. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. (1989) A
prospective study of the risk of tuberculosis among intravenous drug users with
human immunodeficiency virus infection. N Engl J Med 320: 545–550.
12. Mayaud C, Cadranel J (1999) Tuberculosis in AIDS: past or new problems?
Thorax 54: 567–571.
13. World OH Reports, Presentations and Proceedings of the HIV/TB conference
for the Mekong Sub region Ho Chi Minh City, Vietnam 10–14 October 2004
http://wwwunorgvn/who/docs/mekonghivtb/.
14. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006)
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected
with tuberculosis and HIV in a rural area of South Africa. Lancet 368:
1575–1580.
15. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, et al. (2006)
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl
Acad Sci U S A 103: 2869–2873.
16. Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium
tuberculosis and implications for tuberculosis product development. Lancet
Infect Dis 7: 328–337.
17. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM (2004) Stable
association between strains of Mycobacterium tuberculosis and their human host
populations. Proc Natl Acad Sci U S A 101: 4871–4876.
18. Valway SE, Sanchez MP, Shinnick TF, Orme I, Agerton T, et al. (1998) An
outbreak involving extensive transmission of a virulent strain of Mycobacterium
tuberculosis. N Engl J Med 338: 633–639.
19. Manca C, Tsenova L, Barry CE 3rd, Bergtold A, Freeman S, et al. (1999)
Mycobacterium tuberculosis CDC1551 induces a more vigorous host response
in vivo and in vitro, but is not more virulent than other clinical isolates.
J Immunol 162: 6740–6746.
20. Reed MB, Domenech P, Manca C, Su H, Barczak AK, et al. (2004) A glycolipid
of hypervirulent tuberculosis strains that inhibits the innate immune response.
Nature 431: 84–87.
21. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, et al. (2001) Virulence
of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure
to induce Th1 type immunity and is associated with induction of IFN-alpha/
beta. Proc Natl Acad Sci U S A 98: 5752–5757.
22. Brennan PJ, Crick DC (2007) The cell-wall core of Mycobacterium tuberculosis
in the context of drug discovery. Curr Top Med Chem 7: 475–488.
23. Barczak AK, Domenech P, Boshoff HI, Reed MB, Manca C, et al. (2005) In
vivo phenotypic dominance in mouse mixed infections with Mycobacterium
tuberculosis clinical isolates. J Infect Dis 192: 600–606.
24. Manca C, Reed MB, Freeman S, Mathema B, Kreiswirth B, et al. (2004)
Differential monocyte activation underlies strain-specific Mycobacterium
tuberculosis pathogenesis. Infect Immun 72: 5511–5514.
25. Israel N, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, et al. (1989)
Tumor necrosis factor stimulates transcription of HIV-1 in human T
lymphocytes, independently and synergistically with mitogens. J Immunol 143:
3956–3960.
26. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, et al. (1990) Interleukin 6
induces human immunodeficiency virus expression in infected monocytic cells
alone and in synergy with tumor necrosis factor alpha by transcriptional and
post-transcriptional mechanisms. J Exp Med 172: 151–158.
27. Vicenzi E, Alfano M, Ghezzi S, Gatti A, Veglia F, et al. (2000) Divergent
regulation of HIV-1 replication in PBMC of infected individuals by CC
chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and
enhancement by MCP-1. J Leukoc Biol 68: 405–412.
28. Honda Y, Rogers L, Nakata K, Zhao BY, Pine R, et al. (1998) Type I interferon
induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)beta,
repressing the HIV-1 long terminal repeat in macrophages: pulmonary
TB Regulation of HIV-1
PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6116tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med
188: 1255–1265.
29. Zhang Y, Nakata K, Weiden M, Rom WN (1995) Mycobacterium tuberculosis
enhances human immunodeficiency virus-1 replication by transcriptional
activation at the long terminal repeat. J Clin Invest 95: 2324–2331.
30. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related
kinases. Sci STKE 2006: re13.
31. Viedt C, Dechend R, Fei J, Hansch GM, Kreuzer J, et al. (2002) MCP-1 induces
inflammatory activation of human tubular epithelial cells: involvement of the
transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc
Nephrol 13: 1534–1547.
32. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, et al. (2002) Monocyte
chemoattractant protein-1 induces proliferation and interleukin-6 production in
human smooth muscle cells by differential activation of nuclear factor-kappaB
and activator protein-1. Arterioscler Thromb Vasc Biol 22: 914–920.
33. West MJ, Lowe AD, Karn J (2001) Activation of human immunodeficiency virus
transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional
elongation. J Virol 75: 8524–8537.
34. Nabel G, Baltimore D (1987) An inducible transcription factor activates
expression of human immunodeficiency virus in T cells. Nature 326: 711–713.
35. Ranjbar s, Tsytsykova AV, Lee sk, Rajsbaum R, Falvo JV, et al. (2006) NFAT5
Regulates HIV-1 in Primary Monocytes via a Highly Conserved LTR Site.
PLoS Pathogens 2: e130.
36. Berrington WR, Hawn TR (2007) Mycobacterium tuberculosis, macrophages,
and the innate immune response: does common variation matter? Immunol Rev
219: 167–186.
37. Nicod LP (2007) Immunology of tuberculosis. Swiss Med Wkly 137: 357–362.
38. O’Garra A, Britton WJ (2008) Cytokines in Tuberculosis, Kaufmann SHE,
Britton WJ, eds (2008) Handbook of Tuberculosis: Immunology and Cell
Biology, WILEY-VCH Verlag GmbH & KGaA, Weinheim.
39. Collins KR, Quinones-Mateu ME, Wu M, Luzze H, Johnson JL, et al. (2002)
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of
Mycobacterium tuberculosis infection contribute to systemic HIV-1 heteroge-
neity. J Virol 76: 1697–1706.
40. Collins KR, Mayanja-Kizza H, Sullivan BA, Quinones-Mateu ME, Toossi Z, et
al. (2000) Greater diversity of HIV-1 quasispecies in HIV-infected individuals
with active tuberculosis. J Acquir Immune Defic Syndr 24: 408–417.
41. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, et al. (2001) Increased
replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential
mechanisms of viral activation. J Acquir Immune Defic Syndr 28: 1–8.
42. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, et al.
(2001) Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients.
Clin Exp Immunol 123: 233–238.
43. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing
role of tumor necrosis factor in the development of bactericidal granulomas
during BCG infection. Cell 56: 731–740.
44. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, et al. (1998) Abnormalities in
monocyte recruitment and cytokine expression in monocyte chemoattractant
protein 1-deficient mice. J Exp Med 187: 601–608.
45. Haraguchi S, Day NK, Kamchaisatian W, Beigier-Pompadre M, Stenger S, et
al. (2006) LMP-420, a small-molecule inhibitor of TNF-alpha, reduces
replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS
Res Ther 3: 8.
46. Saunders BM, Frank AA, Orme IM, Cooper AM (2000) Interleukin-6 induces
early gamma interferon production in the infected lung but is not required for
generation of specific immunity to Mycobacterium tuberculosis infection. Infect
Immun 68: 3322–3326.
47. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, et al. (2001)
Chemokine receptor 2 serves an early and essential role in resistance to
Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 98: 7958–7963.
48. Ait-Ali D, Turquier V, Tanguy Y, Thouennon E, Ghzili H, et al. (2008) TNF-
{alpha} persistently activates NF-{kappa}B signaling through the TNF-R2 in
chromaffin cells. Implications for long-term regulation of neuropeptide gene
expression in inflammation. Endocrinology 149: 2840–2852.
49. Park SK, Yang WS, Han NJ, Lee SK, Ahn H, et al. (2004) Dexamethasone
regulates AP-1 to repress TNF-alpha induced MCP-1 production in human
glomerular endothelial cells. Nephrol Dial Transplant 19: 312–319.
50. Kinter AL, Biswas P, Alfano M, Justement JS, Mantelli B, et al. (2001)
Interleukin-6 and glucocorticoids synergistically induce human immunodefi-
ciency virus type-1 expression in chronically infected U1 cells by a long terminal
repeat independent post-transcriptional mechanism. Mol Med 7: 668–678.
51. Yang X, Chen Y, Gabuzda D (1999) ERK MAP kinase links cytokine signals to
activation of latent HIV-1 infection by stimulating a cooperative interaction of
AP-1 and NF-kappaB. J Biol Chem 274: 27981–27988.
52. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, et al.
(2000) Functional differences between the long terminal repeat transcriptional
promoters of human immunodeficiency virus type 1 subtypes A through G.
J Virol 74: 3740–3751.
53. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB (1989) Tumor necrosis
factor alpha activates human immunodeficiency virus type 1 through induction
of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.
Proc Natl Acad Sci U S A 86: 5974–5978.
54. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, et al. (2000) A
lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and
CREB binding protein and p300 is recruited to the tumor necrosis factor alpha
promoter in vivo. Mol Cell Biol 20: 6084–6094.
55. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional
regulation of the human monocyte chemoattractant protein-1 gene. Coopera-
tion of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol
Chem 272: 31092–31099.
56. Ahn KS, Aggarwal BB (2005) Transcription factor NF-kappaB: a sensor for
smoke and stress signals. Ann N Y Acad Sci 1056: 218–233.
57. Rohr O, Marban C, Aunis D, Schaeffer E (2003) Regulation of HIV-1 gene
transcription: from lymphocytes to microglial cells. J Leukoc Biol 74: 736–749.
58. Baba M (2006) Recent status of HIV-1 gene expression inhibitors. Antiviral Res
71: 301–306.
59. Rad ME, Bifani P, Martin C, Kremer K, Samper S, et al. (2003) Mutations in
putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing
family. Emerg Infect Dis 9: 838–845.
60. Karboul A, Gey van Pittius NC, Namouchi A, Vincent V, Sola C, et al. (2006)
Insights into the evolutionary history of tubercle bacilli as disclosed by genetic
rearrangements within a PE_PGRS duplicated gene pair. BMC Evol Biol 6:
107.
61. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN (2002) Global
dissemination of the Mycobacterium tuberculosis W-Beijing family strains.
Trends Microbiol 10: 45–52.
62. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D (2002) Worldwide
occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic
review. Emerg Infect Dis 8: 843–849.
63. Streicher EM, Victor TC, van der Spuy G, Sola C, Rastogi N, et al. (2007)
Spoligotype signatures in the Mycobacterium tuberculosis complex. J Clin
Microbiol 45: 237–240.
64. Pillay M, Sturm AW (2007) Evolution of the extensively drug-resistant F15/
LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South
Africa. Clin Infect Dis 45: 1409–1414.
65. Goldfeld AE, McCaffrey PG, Strominger JL, Rao A (1993) Identification of a
novel cyclosporin-sensitive element in the human tumor necrosis factor alpha
gene promoter. J Exp Med 178: 1365–1379.
66. McCaffrey PG, Jain J, Jamieson C, Sen R, Rao A (1992) A T cell nuclear factor
resembling NF-AT binds to an NF-kappa B site and to the conserved
lymphokine promoter sequence ‘‘cytokine-1’’. J Biol Chem 267: 1864–1871.
TB Regulation of HIV-1
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6116